Systemic Fusarium nygamai infection in a patient with lymphoblastic non-Hodgkin's lymphoma.
We report the case history of a 35-year-old male patient with lymphoblastic non-Hodgkin's lymphoma who acquired a systemic infection with Fusarium nygamai during the granulocytopenic phase of cytostatic treatment. The patient survived this infection after haematological recovery and treatment with intravenous amphotericin B (total dose 543 mg). Subsequent chemotherapy courses were not complicated by fungal infections. A recent trip to Egypt and severe chemotherapy-induced mucositis were probably the major causes of this severe infection.
Krulder
J W
JW
Department of Haematology, Municipal Hospital Leyenburg, The Netherlands.
Brimicombe
R W
RW
Wijermans
P W
PW
Gams
W
W
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D005670:Fusarium; D006801:Humans; D008297:Male; D009181:Mycoses / Q000188:drug therapy*; D009503:Neutropenia; D009894:Opportunistic Infections / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications*
D000935:Antifungal Agents; D000666:Amphotericin B